Clinical trials: Covid19- Coronavirus- Sars-cov-2
COVID-19 (Healthy Volunteers)
Study of Recombinant Protein Vaccine Formulations Against COVID-19 in Healthy Adults 18 Years of Age and Older
The primary objectives of the study were: To describe the neutralizing antibody profile at Day 1, Day 22, and Day 36 of each study intervention group.
- Trial name
- NCT04537208
- Testing
- CoV2 preS dTM-AF03 (low-dose), CoV2 preS dTM-AF03 (high-dose), CoV2 preS dTM-AS03 (low-dose)
- Where
- 11 sites in United States
- Volunteers
- 441 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Acute Kidney Failure, Acute Kidney Insufficiency
Kidney Precision Medicine Project (KPMP) - COVID-19 Protocol
Since its inception, KPMP has developed sophisticated protocols for collection and analysis of human kidney tissue, and for collection of biofluids.
- Conditions
- Acute Kidney Failure, Acute Kidney Insufficiency, Acute Renal Failure, Acute Renal Injury
- Trial name
- NCT05384899
- Where
- 4 sites in United States
- Volunteers
- 90 people
- Sponsor
- University of Washington
Emotionnal Distress; COVID-19
Emotional Burden of Healthcare Professionals and Covid Infection 19
COVID-19 ( known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)) has a highly polymorphic clinical presentation, ranging from pauci-symptomatic infection to severe, potentially complicated forms with acute…
- Trial name
- Emocovid (NCT04350099)
- Testing
- quetionnary
- Where
- 3 sites in France
- Volunteers
- 78 people
- Sponsor
- University Hospital, Limoges
SARS-CoV-2
A Study of an Investigational mRNA-1273.815 COVID-19 Vaccine in Previously Vaccinated Adults
To evaluate immune responses of an Investigational mRNA-1273.815 vaccine against the Omicron subvariant strain (XBB.1.5) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- Trial name
- NCT06354998
- Testing
- Investigational mRNA-1273.815, Licensed Spikevax Vaccine
- Where
- 7 sites in Australia
- Volunteers
- 217 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Covid19, COVID-19 Pneumonia
NAC for Attenuation of COVID-19 Symptomatology
The objective of this study is to determine whether oral NAC is effective at attenuating COVID-19 disease symptom severity and duration of symptoms.
- Conditions
- Covid19, COVID-19 Pneumonia, COVID-19 Respiratory Infection, COVID-19 Lower Respiratory Infection
- Trial name
- NACinCOVID2 (NCT05074121)
- Testing
- N-acetylcysteine
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Cambridge Health Alliance
Long COVID-19
Antibodies and Immunity After Vaccination of Recovered Patients With COVID-19 and Long COVID-19 Symptoms
We investigated the association between immune system responsibilities in Long COVID patients and Full recovery patients.
- Trial name
- NCT05484700
- Where
- Thailand
- Volunteers
- 305 people, healthy volunteers welcome
- Sponsor
- Mahidol University
Covid19, SARS-CoV2
Resistance Training and Clinical Status in Patients With Post Discharge Symptoms After Covid-19
COVID-19 survivors commonly exhibit a marked extra-respiratory complication affecting the cardiac (arrhythmias and myocardial injury), renal (acute kidney injury), gastrointestinal, nervous (neuropathy, encephalopathy), endocrine…
- Conditions
- Covid19, SARS-CoV2, Fatigue Syndrome, Chronic, Stress, Psychological
- Trial name
- EXER-COVID (NCT04797871)
- Testing
- Resistance training, Standard care
- Where
- Spain
- Volunteers
- 100 people
- Sponsor
- Universidad Pública de Navarra
COVID
Clinical Trial of Allogeneic Mesenchymal Cells From Umbilical Cord Tissue in Patients With COVID-19
The disease caused by the SARS-CoV-2 virus is a viral disease that infects the lungs, producing flu-like symptoms. Elderly infected patients and/or those with co-morbidities may suffer from acute respiratory distress syndrome due…
- Trial name
- MESCEL-COVID19 (NCT04366271)
- Testing
- Mesenchymal cells, Standard of care
- Where
- 6 sites in Spain
- Sponsor
- Hospital Infantil Universitario Niño Jesús, Madrid, Spain
COVID-19 Infection
Neurological and Neuropsychological Sequelae of COVID-19 Infection
COVID-19 is known to affect the respiratory system but may also have an impact on other organ systems, including the brain. A number of severely ill patients also presents neurological symptoms that may be the result of COVID-19…
- Trial name
- NeNeSCo (NCT04745611)
- Testing
- MRI, Neuropsychological assessment, Questionnaires Patient
- Where
- 3 sites in Netherlands
- Volunteers
- 329 people
- Sponsor
- Maastricht University
Covid19
COVID-19 International Drug Pregnancy Registry
The objective of the COVID-19 International Drug Pregnancy Registry (COVID-PR) is to evaluate obstetric, neonatal, and infant outcomes among women treated with monoclonal antibodies or antiviral drugs indicated for mild…
- Trial name
- COVID-PR (NCT05013632)
- Testing
- Antiviral Agents, Monoclonal antibody
- Where
- United States
- Volunteers
- 2,000 people
- Sponsor
- Pregistry
Pregnancy Related, COVID
imPROving prenaTal carE During ConfinemenT
This study is a non-randomized, quasi-experimental, monocentric study comparing two prenatal monitoring modes in low-risk pregnancy: including at least one remote consultation (phone or teleconsultation) versus face-to-face…
- Trial name
- PROTECT (NCT04368832)
- Testing
- Remote consultation
- Where
- France
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Covid-19, Nosocomial Infection
COG-UK Project Hospital-Onset COVID-19 Infections Study
Hospitals are recognised to be a major risk for the spread of infections despite the availability of protective measures. Under normal circumstances, staff may acquire and transmit infections, but the health impact of within…
- Conditions
- Covid-19, Nosocomial Infection, Coronavirus, Coronavirus Infection
- Trial name
- COG-UK HOCI (NCT04405934)
- Testing
- Use of virus (Covid-19) genome sequence report to inform infection prevention control procedures
- Where
- United Kingdom
- Volunteers
- 2,170 people
- Sponsor
- University College, London
COVID
COVID-19 Impact on Rheumatic Patients
A study to assess the impact of coronavirus disease 2019 (COVID-19) pandemic on the attitude, behaviour and mental health of rheumatic patients and to compare them with healthy individuals.
- Trial name
- NCT04407299
- Testing
- self-administered structured questionnaire
- Where
- Egypt
- Volunteers
- 360 people
- Sponsor
- Cairo University
Covid19
Prevalence of COVID-19 in a French Dependent Care Facility for the Elderly and in a French Long-term Care Unit: Observational Study
The aim of this study is to evaluate the prevalence of COVID-19 among the residents and geriatric inpatients of the care facilities attached to the Centre Hospitalier Sud Essonne (a general hospital located in Ile-de-France…
- Trial name
- SPEED-COVID (NCT04872699)
- Testing
- Serology testing, RT PCR
- Where
- France
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Sud Essonne
COVID-19
Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19)
The primary objective of the study was to evaluate the efficacy and safety of a single dose of RPH-104 (80 mg) or OKZ (64 mg) compared to placebo in addition to standard therapy in patients with severe SARS-CoV-2 infection…
- Trial name
- NCT04380519
- Testing
- RPH-104 80 mg, Olokizumab 64 mg
- Where
- 16 sites in Russia
- Volunteers
- 372 people
- Sponsor
- R-Pharm International, LLC
Severe Acute Respiratory Syndrome, Respiratory Failure
Fibrinolytic Therapy to Treat ARDS in the Setting of COVID-19 Infection
The global pandemic COVID-19 has overwhelmed the medical capacity to accommodate a large surge of patients with acute respiratory distress syndrome (ARDS).
- Conditions
- Severe Acute Respiratory Syndrome, Respiratory Failure, Acute Respiratory Distress Syndrome
- Trial name
- NCT04357730
- Testing
- Alteplase 50 MG [Activase]
- Where
- 9 sites in United States
- Volunteers
- 50 people
- Sponsor
- Denver Health and Hospital Authority
COVID-19, Sars-CoV2
Safety and Feasibility of Allogenic MSC in the Treatment of COVID-19
Coronavirus Disease 2019 (COVID-19) is spreading worldwide and has become a public health emergency of major international concern. Currently, no specific drugs or vaccines are available.
- Trial name
- COVID19 (NCT04467047)
- Testing
- Mesenchymal Stromal Cells infusion
- Volunteers
- 10 people
- Sponsor
- Hospital de Clinicas de Porto Alegre
COVID-19, Convalescent Plasma Treatment
Convalescent Plasma Transfusion in Severe COVID-19 Patients in Jamaica
Corona virus Disease 2019 (COVID-19) can be a severe respiratory illness caused by Severe Acute Respiratory Syndrome (SARS-CoV2) for which there is no standard treatment in affected persons nor a vaccine to prevent the infection.
- Trial name
- NCT04644198
- Testing
- Convalescent Plasma Infusion
- Where
- Jamaica
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- The University of The West Indies
Corona Virus Infection, SARS-CoV 2
Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia
This is a single arm phase II trial to assess efficacy and confirm safety of infusions of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms,with or without confirmed interstitial…
- Conditions
- Corona Virus Infection, SARS-CoV 2, SARS Pneumonia, Pneumonia
- Trial name
- NCT04374565
- Testing
- High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
- Where
- 2 sites in United States
- Volunteers
- 29 people
- Sponsor
- University of Virginia
SARS-CoV Infection, Acute Respiratory Distress Syndrome
Glenzocimab in SARS-Cov-2 Acute Respiratory DistrEss syNdrome Related to COVID-19
A randomized, double blind, multicenter, placebo-controlled, parallel group, fixed dose, phase II study to evaluate the efficacy and safety of glenzocimab in ARDS.
- Conditions
- SARS-CoV Infection, Acute Respiratory Distress Syndrome, COVID-19, ARDS
- Trial name
- GARDEN (NCT04659109)
- Testing
- glenzocimab
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Acticor Biotech
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.